Immuneering Corp IMRX
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Immuneering Corp (IMRX) is a healthcare company listed in the US with a market value of about $240M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -47%.
About Immuneering
Immuneering is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 67% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $316952 | $2M | $2M |
| Net income | -$56M | -$61M | -$53M | -$51M | -$34M | -$17M |
| Free cash flow | -$45M | -$55M | -$49M | -$45M | -$31M | -$15M |
| EPS (diluted) | $-1.27 | $-2.04 | $-1.88 | $-1.91 | $-2.46 | $-3.44 |
| Net margin | — | — | — | -15937.3% | -1612.3% | -737.2% |
| ROIC | -21.1% | -111.1% | -48.5% | -35.6% | -20.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $17.00, 358% above the current price; targets range from $11.00 to $30.00; the consensus rating is “Strong buy”; expected EPS is $-1.26 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Immuneering pay a dividend?
Not currently.
Is Immuneering a good stock to buy?
We do not give buy or sell advice. Immuneering scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.